#Netherlands #Leiden #Qurin® #Qatra™ #DNA Extraction

Qurin® Launches Qatra™ Genomic DNA Extraction Kit

In a significant advancement for liquid biopsy diagnostics, Qurin® has officially launched its Qatra™ Genomic DNA Extraction Laboratory Kit, a product tailored for extracting genomic DNA (gDNA) from large volumes of urine—ranging from standard laboratory samples of 40-50 mL up to a substantial 400 mL.

Addressing Urgent Needs in Molecular Research

Urine is an overlooked source of biological information, owing to its accessibility and non-invasive nature. Currently, limitations in processing large urine volumes impede researchers from accessing vital molecular data necessary for advancing health outcomes. By utilizing the Qatra kit, researchers can tap deeper into the biological material that urine holds, significantly increasing genomic data yield by up to 7.6 times when comparing a 400 mL sample to standard smaller samples. With innovative proprietary technology involving a specialized magnetic bead surface chemistry, Qurin offers a streamlined approach to DNA extraction.

Innovative Design Aimed at Efficiency

With the Qatra kit, the process flow has been simplified into a unified workflow, which minimizes the need for extensive sample handling and frees up researchers' time. The proprietary magnetic retrieval system, also under patent pending, efficiently captures DNA-loaded beads from large sample volumes, ensuring high recovery rates. Unlike current protocols that necessitate the concentration or multiple extractions from large urine samples, Qatra supports automated workflows—paving the way for higher throughput in both laboratory and clinical settings.

Internal studies by Qurin emphasize the meaningful impact of large-volume processing. As sample volume escalates, researchers uncover a robust potential for recovering DNA—particularly beneficial when investigating low-concentration biomarkers imperative for accurate diagnostics.

The Broader Qatra Research and Development Program

The Qatra kit marks a pivotal milestone within Qurin's wider RD Program, aimed at harnessing biomarker technology from urine. This endeavor not only targets oncology diagnostics but anticipates expanding into areas beyond urogenital cancers, reflecting the versatility of urinary biomarkers including tumor-derived circulating cell-free DNA. Given the challenges of low biomarker concentrations, Qurin's advancements can significantly enhance the capacity to access and study vital genetic material.

As the Qatra RD Program evolves, it will serve as a flexible platform that adapts to various biomarker types—catering to genomic DNA, RNA, proteins, and extracellular vesicles. Its innovative design envisions the application of bead-based modules for laboratory work as well as cartridge-based modules for at-home sample collection and biomarker extraction—ultimately transforming the landscape of molecular analysis.

A Vision for the Future of Urine-Based Diagnostics

"Urine has tremendous potential for molecular analysis, but we need technologies designed to meet the unique characteristics of the sample," asserts Marc Peeters, CEO of Qurin. With Qatra, the mission is clear: optimize the utilization of available urine, capture more molecular information, and facilitate this process to ensure scalability for future research initiatives.

Currently, the Qatra genomic DNA Extraction Lab Kit is designated for Research Use Only (RUO) and remains outside the scope of diagnostic applications. However, Qurin's ambition for strategic innovation in extracting and analyzing urinary biomarkers positions it well for leading the future in clinical insights derived from non-invasive sample types.

In summary, with the introduction of the Qatra extraction kit, Qurin is poised to revolutionize how researchers approach urine as a valuable source of genetic data, enriching the scope of molecular diagnostics and paving the way for enhanced patient outcomes in the realm of oncology. For further details, visit www.qurin.com.